Gleolan FDA Approval History
FDA Approved: Yes (First approved June 6, 2017)
Brand name: Gleolan
Generic name: aminolevulinic acid hydrochloride
Dosage form: Oral Solution
Company: NX Development Corp.
Treatment for: Optical Imaging During Glioma Surgery
Gleolan (aminolevulinic acid hydrochloride) is an optical imaging agent indicated for use in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Development timeline for Gleolan
| Date | Article |
|---|---|
| Jun 6, 2017 | Approval FDA Approves Gleolan (aminolevulinic acid hydrochloride) as an Optical Imaging Agent in Patients with Gliomas |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
